Tech Company Financing Transactions
Kelonia Therapeutics Funding Round
Alta Partners, Horizons Ventures and private investors participated in a $50 million Series A funding round for Kelonia Therapeutics. This venture round was announced by the company on 4/28/2022.
Transaction Overview
Company Name
Announced On
4/28/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Proceeds Purpose
The company will use the funding to redefine what's possible for genetic medicines starting with an "off-the-shelf" chimeric antigen receptor (CAR) to treat hematologic cancer that may enable the unrivalled clinical benefit of CAR T without the typical toxicities and with the ease of access of conventional medicines
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Undisclosed, Undisclosed
Undisclosed
Undisclosed, Undisclosed
Undisclosed
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our goal is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Kevin Friedman
VP - Finance
Ryan Lynch
Browse more venture capital transactions:
Prev: 4/28/2022: CommandBar venture capital transaction
Next: 4/28/2022: Madison Reed venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs